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ABSTRACT 
Background: Vaccinations for COVID-19 have been prioritised for older people living in care homes. However, 
vaccination trials included limited numbers of older people.  
 
Aim: We aimed to study infection rates of SARS-CoV-2 for older care home residents following vaccination 
and identify factors associated with increased risk of infection.  
 
Study Design and Setting: We conducted an observational data-linkage study including 14,104 vaccinated 
older care home residents in Wales (UK) using anonymised electronic health records and administrative data.  
 
Methods: We used Cox proportional hazards models to estimate hazard ratios (HRs) for the risk of testing 
positive for SARS-CoV-2 infection following vaccination, after landmark times of either 7 or 21-days post-
vaccination. We adjusted hazard ratios for age, sex, frailty, prior SARS-CoV-2 infections and vaccination type. 
 
Results: We observed a small proportion of care home residents with positive PCR tests following vaccination 
1.05% (N=148), with 90% of infections occurring within 28-days. For the 7-day landmark analysis we found a 
reduced risk of SARS-CoV-2 infection for vaccinated individuals who had a previous infection; HR (95% 
confidence interval) 0.54 (0.30,0.95), and an increased HR for those receiving the Pfizer-BioNTECH vaccine 
compared to the Oxford-AstraZeneca; 3.83 (2.45,5.98). For the 21-day landmark analysis we observed high 
HRs for individuals with low and intermediate frailty compared to those without; 4.59 (1.23,17.12) and 4.85 
(1.68,14.04) respectively. 
 
Conclusions: Increased risk of infection after 21-days was associated with frailty. We found most infections 
occurred within 28-days of vaccination, suggesting extra precautions to reduce transmission risk should be 
taken in this time frame. 
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Vaccinations for SARS-CoV-2 in the UK have been prioritised to older people living in care homes [1], [2]. 
However, the efficacy of the COVID-19 vaccine in older people is relatively unknown, with very few trials 
recruiting older people and older people with frailty [3]. Specifically, the Oxford–AstraZeneca vaccine trials 
had less than 4% of participants over 70 years of age and those with comorbidities were a minority [4]. 
Similarly, the initial Pfizer BioNTECH trials included only 774 individuals aged 75 or over and 3,848 individuals 
aged 65 and over from a total of 18,198 vaccinated individuals [5]. 
 
Care homes are a keystone of adult social care. They provide accommodation and care for those needing 
substantial help with personal care, but more than that, they are people’s homes [6], [7]. In 2016, there were 
11,300 care homes in the UK, with a total of 410,000 residents [8]. Within care homes people live in proximity, 
and may live with frailty and many different health conditions, making them susceptible to outbreaks of 
infectious disease [6]. COVID-19 is described  by Lithande et al, as ‘…a dynamic, specific and real threat to the 
health and well-being of older people’ (2020,p.10) [9]. The impacts of COVID-19 on this sub-population have 
been reported widely in both international and UK media, and in a growing peer reviewed literature. 
 
Here, we produced a rapid report, in near real-time, on the risk of SARS-CoV-2 infection for vaccinated care 
home residents. This is the first study we are aware of investigating this vulnerable sub-population. 
Furthermore, we included information on previous positive SARS-CoV-2 PCR tests, age, sex, and frailty. We 
were able to do this using the existing infrastructure and linked data from the Secure Anonymised 
Information Linkage (SAIL) Databank [10]–[12].  
 
Methods 
Study design and setting 
We conducted an observational data-linkage study for older care home residents in Wales (UK). We used 
data on 14,104 individuals receiving a SARS-CoV-2 vaccination from 4th December 2020 to 12th February 2021 
and testing data from 4th December 2020 to 4th March 2021 to investigate positive SARS-CoV-2 PCR tests 
following a vaccination.  
 
Data sources 
We used linked longitudinal data from the SAIL Databank to create our datasets [10]–[12]. Specifically, we 
used the COVID Vaccine Dataset (CVD) to identify individuals living in care homes who had received a 
vaccination. We included all individuals identified as an ‘older adult resident in a care home’. The Pathology 
COVID-19 Daily (PATD) data was used to identify dates of positive SARS-CoV-2 PCR tests. A cleaned and pre-
linked version of the Welsh Demographic Service Dataset (WDSD) was used to determine demographic 
information for each individual [13]. We also linked to the Patient Episode Database for Wales (PEDW) to 
include an indication of frailty. 
 
Hospital Frailty Risk Score 
The Hospital Frailty Risk Score (HFRS) was developed using Hospital Episode Statistics (HES), a database 
containing details of all admissions, Emergency Department attendances and outpatient appointments at 
NHS hospitals in England, and validated on over one million older people using hospitals in 2014/15 [14]. The 
HFRS uses the International Classification of Disease version 10 [15] (ICD-10) codes to search for specific 
conditions from secondary care. A weight is then applied to the conditions and a cumulative sum is used to 
determine a frailty status of: Low, Intermediate or High. We additionally included a HFRS score of ‘No score’ 
for people who had not been admitted to hospital in the look back period. We calculated the HFRS using the 
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Patient Episode Database for Wales (PEDW), the Welsh counterpart to HES, on the vaccination date, with a 
two year look back of all hospital admissions recorded in Wales. 
 
Variables 
Our outcome of interest was the time to a positive SARS-CoV-2 PCR test following a vaccination. Individuals 
were censored for death or the end of study period. We included covariates for previous positive SARS-CoV-
2 PCR tests (yes/no), age (continuous), sex (male/female), frailty (HFRS: no-score, low, intermediate, high), 
and vaccine manufacturer (Oxford-AstraZeneca, Pfizer-BioNTECH). Previous positive SARS-CoV-2 PCR tests 
were identified at any time point before vaccination. 
 
Statistical methods  
We included basic demographic information and investigated differences between individuals who had a 
positive SARS-CoV-2 PCR test following vaccination. We produced a Kaplan-Meier survival curve and an 
empirical cumulative distribution function for the time to first positive SARS-CoV-2 PCR test following 
vaccination. We also calculated Hazard Ratios (HR) for our covariates using univariable and multivariable Cox 
proportional hazards models. For the Cox proportional hazards models we defined two landmark periods for  
immunisation, 7 and 21-days. In a landmark analysis, only those who have not had an event (positive PCR 
test) for the specified time period are included. In other words, individuals who had a positive SARS-CoV-2 
PCR test within the 7 and 21-day periods were removed from the respective analyses, see Figure S1 for an 
example. We included these periods as a proxy for the varying number of days for the vaccine to become 
effective. As a sensitivity analysis we repeated the analysis with the 7 and 21-day immunisation (landmark) 
periods, but applied a maximum follow-up of 14-days. Individuals were right censored for death or the end 
of the study period, whichever occurred first. Violations of the proportional hazards assumption were tested 
for using Schoenfeld residuals. 
 
Results 
We identified 14,501 vaccinated older adult residents in a care home in the CVD dataset. We removed 240 
residents prior to analysis due to incomplete demographic information. We restricted the age group to those 
aged 60+, removing a further 157 individuals, resulting in 14,104 residents used for analysis. The basic 
demographic information for the total cohort and the cohort stratified by those who had a subsequent 
positive SARS-CoV-2 PCR test following vaccine is presented in   
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Table 1. Figure 1 shows the Kaplan-Meier curve for the time to first positive PCR test following vaccination. 
The curve indicates an overall small proportion of individuals testing positive following vaccination. Figure 2 
shows the empirical cumulative distribution function for the times between first positive PCR test and 
vaccination. The Kaplan-Meier curve and empirical cumulative distribution function suggest a susceptible 
period of vaccinated individuals up to 42 days, with approximately 40% of individuals having a positive PCR 
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Table 1. Demographic information for the total cohort and the cohort stratified by those who had a subsequent positive SARS-CoV-
2 PCR test following vaccination. 
  Positive PCR Test Post Vaccine  
Total No Yes 
N 14,104 13,956 (98.95%) 148 (1.05%) 
Previous Covid Infection 2,868 (20.3%) 2,848 (20.4%) 20 (13.5%) 
Mean Age (S.D) 85      (8.3) 85.1      (8.3) 84.5      (8.4) 
Sex 
   
Male 4,096 (29.0%) 4,045 (29.0%) 51 (34.5%) 
Female 10,008 (71.0%) 9,911 (71.0%) 97 (65.5%) 
Hospital Frailty Risk Score 
   
No Score 6,409 (45.4%) 6,356 (45.5%) 53 (35.8%) 
Low 1,149   (8.1%) 1,138   (8.2%) 11   (7.4%) 
Intermediate 3,009 (21.3%) 2,969 (21.3%) 40    (27%) 
High 3,537 (25.1%) 3,493 (25.0%) 44 (29.7%) 
Vaccine Type 
   
Oxford-Astrazeneca 12,571 (89.1%) 12,459 (89.3%) 112 (75.7%) 
Pfizer-BioNTECH 1,533 (10.9%) 1,497 (10.7%) 36 (24.3%) 
 
Hazard Ratios and 95% confidence intervals for the Cox proportional hazards models are presented in Table 
2 and Table 3. In our multivariable analyses, we found a reduced risk of SARS-CoV-2 infection for vaccinated 
individuals who had a previous infection after a 7-day immunisation period; HR (95% confidence interval) 
0.54 (0.30,0.95), and an increased risk for those receiving the Pfizer-BioNTECH vaccine HR 3.83 (2.45,5.98). 
The 21-day immunisation period multivariable model indicated frailty as a risk factor, with low frailty having 
a HR of 4.59 (1.23,17.12) and intermediate frailty with a HR of 4.85 (1.68,14.04). The Schoenfeld residual test 
indicated only the 21-day immunisation / 14-day observation model deviated from the proportional hazards 
assumption at the 95% level (p-value 0.04), all other models met proportional hazards assumptions. 
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Figure 2. Cumulative Distribution Function (CDF) for the time between vaccination and first positive PCR test (N = 148).  
Figure 1.  Kaplan-Meier curve for the time to the first positive SARS-COV-2 PCR test following vaccination.  
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Table 2. Univariable and multivariable Cox Proportional Hazards models with 7 and 21-day landmark times applied to the cohort. Hazard ratios and presented with 95% confidence 
intervals. Results that are statistically significant at the 95% level are highlighted in bold font. 
 7-day landmark time 21-day landmark time 
HRs (95% CI) Univariable Multivariable Univariable Multivariable 
Age 1.004 (0.98,1.028) 1.01 (0.985,1.036) 1.024 (0.976,1.074) 1.031 (0.981,1.084) 
Previous positive PCR test (Reference: 
No) 
    
Yes 0.667 (0.379,1.175) 0.535 (0.301,0.949) 0.931 (0.353,2.46) 0.807 (0.301,2.159) 
Sex (Reference: Female) 
    
Male 1.39 (0.919,2.104) 1.428 (0.929,2.195) 1.246 (0.56,2.773) 1.285 (0.563,2.932) 
Hospital Frailty Risk Score (Reference: 
No score) 
    
Low 1.597 (0.791,3.226) 1.605 (0.794,3.244) 4.487 (1.205,16.71) 4.585 (1.229,17.12) 
Intermediate 1.645 (0.996,2.717) 1.767 (1.066,2.927) 4.662 (1.62,13.417) 4.852 (1.677,14.04) 
High 1.298 (0.777,2.168) 1.374 (0.82,2.303) 2.511 (0.797,7.913) 2.574 (0.813,8.15) 
Vaccine (Reference: Oxford 
Astrazeneca) 
    
Pfizer-BioNTECH 3.362 (2.166,5.216) 3.829 (2.452,5.979) 1.921 (0.727,5.077) 2.196 (0.821,5.873) 
- - - - - 
Observations 13,989 13,989 13,605 13,605 
Events 97 97 27 27 
- - - - - 
Concordance 
 
0.669  (s.e. 0.028 ) 
 
0.693  (s.e. 0.052 ) 
     
Global Schoenfield residual     
Chi-squared  8.9  7.8 
Degrees of freedom  7  7 
p-value  0.26  0.35 
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Table 3. Univariable and multivariable Cox Proportional Hazards models with 7 and 21-day landmark times applied to the cohort and a maximum 14-day observation period. Hazard 
ratios and presented with 95% confidence intervals. Results that are statistically significant at the 95% level are highlighted in bold font. 
 
7-day landmark, 14-day observation 21-day landmark, 14-day observation 
HRs (95% CI) Univariable Multivariable Univariable Multivariable 
Age 0.998 (0.97,1.025) 1.005 (0.977,1.034) 1.012 (0.963,1.064) 1.014 (0.963,1.068) 
Previous positive PCR test 
(Reference: No) 
    
Yes 0.549 (0.273,1.102) 0.435 (0.215,0.881) 0.808 (0.276,2.364) 0.693 (0.233,2.055) 
Sex (Reference: Female) 
    
Male 1.526 (0.952,2.446) 1.584 (0.969,2.589) 1.025 (0.425,2.471) 0.995 (0.402,2.462) 
Hospital Frailty Risk Score 
(Reference: No score) 
    
Low 1.047 (0.438,2.505) 1.04 (0.434,2.49) 2.247 (0.436,11.58) 2.307 (0.447,11.911) 
Intermediate 1.136 (0.631,2.045) 1.226 (0.679,2.216) 4.251 (1.453,12.436) 4.479 (1.523,13.169) 
High 1.027 (0.576,1.829) 1.095 (0.612,1.958) 2.528 (0.802,7.967) 2.653 (0.838,8.401) 
Vaccine (Reference: Oxford 
Astrazeneca) 
    
Pfizer-BioNTECH 3.78 (2.307,6.194) 4.316 (2.616,7.121) 1.646 (0.563,4.817) 1.917 (0.647,5.682) 
- - - - - 
Observations 13,989 13,989 13,605 13,605 
Events 73 73 24 24 
- - - - - 
Concordance 
 
0.684  (s.e. 0.032 ) 
 
0.681  (s.e. 0.056 ) 
     
Global Schoenfield residual     
Chi-squared  6.2  14.5 
Degrees of freedom  7  7 
p-value  0.51  0.04 
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Discussion 
Our study focussed on older adults resident in care homes. This is a particularly vulnerable sub-population 
that has not previously been studied in relation to infection rates for SARS-CoV-2 following vaccination, and 
which has suffered considerably from the most severe effects of the pandemic. Our study used a large cohort 
of 14,104 individuals, which is comparable to the entire case population of the ChAdOx1 nCoV-19 vaccine (N 
= 12,174) [4]. We were also able to include information on frailty, previous infections and vaccination 
received. 
 
We found 148 (1.05%) of individuals in our cohort had a positive PCR-test following vaccination. The Kaplan-
Meier curve and empirical cumulative distribution function suggest a susceptible period for infection of up 
to 42-days, with approximately 99% of infections occurring within this period. It is well known that there is a 
delay following immunisation for the vaccine to be effective, but this highlights the need for extended 
vigilance during this period for this highly vulnerable care home population.  
 
We found a large, and statistically significant reduced risk for infection post vaccine for individuals who had 
already had a SARS-CoV-2 infection. The risk was approximately halved, and those who had a prior infection 
may be more robust and have existing antibodies, leading to a reduced risk to subsequent infections. 
Increased levels of frailty, determined by the HFRS, were associated with substantially increased risk of 
infection post vaccine (up to almost 5-fold increase for intermediate frailty in the 21-day landmark post 
vaccination). Frailty is complex, and those living with high levels of frailty may need additional support. In 
particular, increased care requires additional contact with carers, and subsequently an increased risk of 
transmission of SARS-CoV-2 compared to those who are more independent or can be isolated. We note that 
the effect was not quite as large in the highest frailty group. This simply may reflect uncertainty in the risk 
estimates, or may be the result of more complex management or identification of risk in this group. 
 
In the 7-day landmark analysis there was evidence to suggest an increased risk of infection post vaccination 
for those receiving the Pfizer-BioNTECH vaccine compared to the Oxford-AstraZeneca vaccine, but no 
statistically significant difference in the 21-day landmark analysis. This suggests the Oxford-AstraZeneca 
vaccine has a potentially shorter time to become effective in our cohort. 
 
Strengths 
This analysis was possible using the existing infrastructure of the SAIL Databank and we will continue to 
investigate adverse events for individuals receiving a vaccination. We were able to rapidly develop and 
analyse a large cohort of care home residents with the inclusion of individual level information. 
 
Limitations 
Due to the nature of the vaccination rollout, we only had a limited follow-up time and subsequently a small 
number of events. At the time of analysis we did not include information on second doses due to very small 
numbers. We will continue to monitor the care home population and will update our analysis with an 
extended follow-up time and second doses when possible. In further work we aim to include background 
prevalence of COVID-19, and multi-morbidities and we will investigate additional adverse events such as 
mortality and hospitalisation. 
 
Conclusion 
Our findings suggest care home residents with frailty are the most susceptible to infection post vaccination 
and should be prioritised for a second dose of the SARS-CoV-2 vaccine. We also found a susceptible period 
of reinfection of up to 42-days, indicating extra care and precautions should be taken in this period. 
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Figure S1. Immunisation (landmark) analysis timeline example. 
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